Status:
RECRUITING
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Greece
Lead Sponsor:
AbbVie
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well Venetoclax works to treat AML in adult particip...
Eligibility Criteria
Inclusion
- Participant diagnosed Acute Myeloid Leukemia (AML) who is ineligible to intensive chemotherapy and is eligible to receive venetoclax as a first-line therapy, as per Greek Ministry of Health (MOH) label.
- Physician has decided to initiate venetoclax treatment. The decision to treat with venetoclax is made by the physician in accordance with the local label prior to any decision to approach the patient to participate in this study.
Exclusion
- \- Participating in an interventional clinical trial within 30 days prior to venetoclax treatment initiation.
Key Trial Info
Start Date :
May 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05317494
Start Date
May 26 2022
End Date
December 1 2026
Last Update
July 16 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Olympion General Clinic /ID# 268392
Pátrai, Achaia, Greece, 25443
2
General Hospital of Athens Gennimatas /ID# 245968
Athens, Attica, Greece, 11527
3
General Hospital of Athens Laiko /ID# 244338
Athens, Attica, Greece, 11527
4
University General Hospital Attikon /ID# 248265
Athens, Attica, Greece, 12462